Efficacy and Safety of Novel Antibiotic Adjuvant Entity in Hospital Acquired Pneumonia Treatment

Background and Objective: A multiple number of studies have reported that CSE-1034, an antibiotic adjuvant entity (AAE) of Ceftriaxone-Sulbactam-Ethylenediaminetetraacetic acid (EDTA) is an effective antibiotic for the treatment of various bacterial infections ranging from mild to severe in grade, wherein EDTA acts as antibiotic resistance breaker. The objective of this study was to evaluate the clinical outcome of use of CSE-1034 empirically in hospital acquired pneumonia (HAP) patients. Moreover, as EDTA is widely used anti-coagulant, the other objective included the effect of CSE-1034 on the blood hemostasis.

Methods: This retrospective study was conducted on HAP patients who received CSE-1034 as an empirical treatment to analyze the efficacy and safety of CSE-1034. CSE-1034 therapy was started empirically in all these subjects and continued or discontinued based on culture susceptibility profile and clinical response. The clinical response of the therapy was evaluated in terms of improvement in clinical parameters.

Results: 25 adult patients were included in this study. The most common pathogen isolated was K. pneumoniae distantly followed by E. coli. Ninety-two percent (23/25) patients who received CSE-1034 empirically were cured with CSE-1034 monotherapy and 8% (2/25) with CSE-1034+Colistin combination therapy. Moreover, no significant alteration in Prothrombin time (PT) and International Normalized Ratio (INR) values were observed in any of the patients during the course of treatment with CSE-1034.

Conclusion: From this study, it is concluded that CSE-1034 alone or in combination with Colistin can serve as an effective and safe option for the treatment of HAP. Moreover, CSE-1034 can be considered as safe drug as no abnormal changes in PT/INR were observed.